Healthcare / Drug Manufacturers - Specialty & GenericBSE
$313.40
+13.05 (+4.34%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $625.0M · quality 61.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$9.0B
P/E
12.8x
↓EV/EBITDA
7.6x
↓ROE
17.7%
↑Gross Margin
63.5%
↑Debt/Equity
0.28
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+14.6%
FCF CAGR
-6.2%
FCF margin
11.9%
FCF / Net income
0.87x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.25B · net income $717.7M · FCF $625.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.25B | $5.25B | $4.69B | $3.33B | $3.49B |
| Net Income | $717.7M | $717.7M | $768.6M | $-230.6M | $-510.8M |
| EBITDA | $1.29B | $1.29B | $1.22B | $307.9M | $-40.7M |
| EPS | — | — | 26.35 | -7.99 | -17.70 |
| Gross Margin | 63.5% | 63.5% | 66.3% | 57.1% | 53.1% |
| Operating Margin | 14.9% | 14.9% | 18.2% | 2.8% | -0.3% |
| Net Margin | 13.7% | 13.7% | 16.4% | -6.9% | -14.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.28 | 0.28 | 0.32 | 0.48 | 0.70 |
| Cash Flow | |||||
| Free Cash Flow | $625.0M | $625.0M | $187.7M | $861.4M | $756.2M |
| Returns | |||||
| ROE | 17.7% | 17.7% | 21.2% | -8.0% | -16.2% |
| Valuation | |||||
| P/E | 12.79 | 12.79 | 10.78 | — | — |
| EV/EBITDA | 7.59 | 7.59 | 7.52 | 19.73 | — |
| P/B | 2.21 | 2.21 | 2.28 | 1.70 | 1.24 |
| Growth & Yield | |||||
| Revenue Growth | 11.9% | 11.9% | 40.8% | -4.5% | — |
| EPS Growth | — | — | 429.8% | 54.9% | — |
| Dividend Yield | 0.8% | 0.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+5.3%
Start / end P/E
n/dx → n/dx
EPS bridge
26.35 → n/d
Residual
+4.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.